Compare iShares 7-10 Year Treasury Bond ETF (IEF) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares 7-10 Year Treasury Bond ETF vs Sanofi SA — how do they compare? iShares 7-10 Year Treasury Bond ETF trades at $89.34 (market cap $41.13B), while Sanofi SA trades at $40.2 (market cap $95.18B). The key difference: Sanofi SA is far larger — about 2.3× iShares 7-10 Year Treasury Bond ETF's market cap, and Sanofi SA pays a 6.01% dividend while iShares 7-10 Year Treasury Bond ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares 7-10 Year Treasury Bond ETF for 108 Days and Sanofi SA for 94 Days on average.
| IEF | SNY | |
|---|---|---|
Market Cap | $41.13B | $95.18B |
Volume | 10,340,382 | 2,995,646 |
Sector | Fixed Income | Health |
52-Week High | $97.99 | $52.34 |
52-Week Low | $88.92 | $39.51 |
Typical Hold Time | 108 Days | 94 Days |
Enterprise Value | — | $114.48B |
Dividend Yield | — | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IEF is trading at $89.11, down 0.02% with a bearish technical outlook. The fund shows neutral oscillators but bearish moving averages, with RSI levels below 30 indicating potential oversold conditions. Recent dividend payments of $0.31-$0.33 provide income support amid market volatility. The bond market faces pressure from rising Treasury yields and inflation concerns.
The outlook remains cautious as Treasury yields near multi-decade highs create headwinds for bond ETFs. While current yields offer attractive entry points for income investors, persistent inflation and Fed policy uncertainty pose significant risks. Defensive positioning in fixed income suggests limited near-term upside potential.
SNY trades at $40.2, up 1.62% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue grew to $46.72B in 2025, and net income improved to $7.81B. Analyst consensus is mixed, with 44% buy ratings. Recent news highlights a major immunology alliance expansion with Regeneron, valued up to $8B, signaling growth initiatives beyond Dupixent.
The outlook for SNY is cautiously optimistic, driven by earnings momentum and strategic partnerships, but faces risks from patent expirations and volatile cash flows. Investment opportunity lies in pipeline diversification and cost management, while investors should monitor competitive pressures and R&D execution. The stock's current valuation metrics suggest reasonable pricing relative to peers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares 7-10 Year Treasury Bond ETF
The underlying index measures the performance of public obligations of the US Treasury that have a remaining maturity of greater than or equal to seven years and less than ten years. The fund will invest at least 80% of its assets in the component securities of the underlying index, and the fund will invest at least 90% of its assets in US Treasury securities that the advisor believes will help the fund track the underlying index.
Read more on IEF →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
